ClinicalTrials.gg
CompletedNCT03468725Updated Sep 18, 2018

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

A Phase 1 interventional study of XPF-008 and Microcrystalline Cellulose in Healthy Male Volunteers, sponsored by Xenon Pharmaceuticals Inc.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-18.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The XEN1101 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will eventuate the safety, tolerability, pharmacokinetics (PK) and effects on transcranial magnetic stimulation (TMS) of oral doses of XEN1101 in healthy male subjects.The TMS procedure is designed to demonstrate delivery of XEN1101 into the central nervous system and to observe a change in cortical excitability as measured by EEG and/or EMG activity. It is estimated there will be approximately 15 subjects in the planned study.

02

Conditions studied

  • Healthy Male Volunteers

Keywords

  • Transcranial magnetic stimulation
03

In context

Lead sponsor

Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy male aged between 18 and 55 years inclusive with a (BMI) between 18.5 and 30.0 kg/m2
  • Right-handed only
  • Must agree to use effective methods of , if applicable
  • Able to swallow multiple capsules
  • Able to provide written, personally signed and dated Form

Key Exclusion Criteria:

  • Any current and relevant history of significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk, affect clinical or laboratory results, or the subject's ability to participate in the study
  • Any abnormalities in vital signs, ECGs, physical examinations, or laboratory evaluations
  • Answering "yes" to any of the questions within the Columbia Suicide Severity Rating Scale Mental incapacity or language barriers precluding adequate understanding, cooperation, and compliance with the study
  • No prescription or over-the-counter (OTC) medications (including multivitamins, herbal or homeopathic preparations 14 days or if applicable/available, 5 half-lives prior to dosing to study end
  • Any history of severe head trauma
  • No smoking 60 days prior to dosing to study end
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    XPF-008

    Single oral dose

    Drug: XPF-008

  • Active comparator
    Placebo

    Single oral dose

    Drug: Microcrystalline Cellulose

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) as assessed by CTCAE v4.03

    To assess AEs as a criteria of safety and tolerability

    Time frame: From screening (28 days prior to Day 1) through to 30 days post-final dose

  2. Resting 12-lead electrocardiogram (ECG)

    To assess ECG intervals (PR, QRS, QTcF, RR) as a criteria of safety and tolerability

    Time frame: From screening (28 days prior to Day 1) through to Day 14

  3. Number of participants with vital sign abnormalities

    To assess vital signs as a criteria of safety and tolerability

    Time frame: From screening (28 days prior to Day 1) through to Day 14

  4. Pharmacodynamic (PD) Effects assessed by Transcranial Magnetic Stimulation (TMS) biological markers of brain excitability

    To assess biological marker of brain excitability: amplitude (in uV) of TMS evoked potentials on the EEG

    Time frame: Day 1 predose through to Day 7

  5. PD Effects assessed by TMS biological markers of brain excitability

    To assess biological marker of brain excitability: resting motor threshold (in %) for elicitation of an electromyographic response

    Time frame: Day 1 predose through to Day 7

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Cmax is the maximum observed plasma concentration in ng/mL

    Time frame: Day 1 predose through to Day 8

  2. Terminal elimination half-life (t1/2)

    The time in hours required for the plasma level of the study drug to decrease by one-half during the terminal elimination phase

    Time frame: Day 1 predose through to Day 8

  3. Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC0-last)

    The area under the plasma concentration-time curve \[in ng.h/mL\] from time zero to the time corresponding to the last quantifiable plasma concentration

    Time frame: Day 1 predose through to Day 8

07

Study locations

1 site
  • King's College Hospital
    Brixton, London SE5 9RS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jul 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 16, 2018
StartActual
Feb 13, 2018
Primary completionActual
Jul 31, 2018
CompletionActual
Jul 31, 2018
Last update
Sep 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03468725
Responsible party
Sponsor
First posted
Mar 16, 2018
Start date
Feb 13, 2018
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018
Last update
Sep 18, 2018

Study contacts

Gregory Beatch, PhD
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion